Likelihood of being at extremes of nightly sleep duration further increased with heavy cannabis use
Sleep Disorders
New Indication: Xywav
Xywav is now approved for the treatment of idiopathic hypersomnia in patients aged 18 years and older.
Daytime Sleepiness, PAP Adherence, and Satisfaction in OSA Patients
Sleep apnea research presented at CHEST 2021 examined links between PAP therapy adherence and the prevalence and severity of excessive daytime sleepiness.
Bedwetting May Improve After Adenotonsillectomy for Sleep Apnea
Findings seen in secondary analysis of data for children randomly assigned to adenotonsillectomy or watchful waiting for nonsevere OSA
Recall of Philips Breathing Machines Affects Millions of Americans
About 2 million of the recalled machines were in use in the United States
Xywav Approved for Idiopathic Hypersomnia
The approval was based on data from a phase 3 study that assessed Xywav in adults with idiopathic hypersomnia.
Obstructive Sleep Apnea May Raise Risk for Sudden Death
Meta-analysis shows sleep apnea linked to increased risk for sudden death, cardiovascular mortality
Oral Orexin Agonist Gets Breakthrough Therapy Status for Narcolepsy Type 1
The Company is currently investigating TAK-994 in adults with narcolepsy type 1 or type 2 in a phase 2 study.
AHA Advises OSA Screening for Those With CV Risk, Conditions
Screening for obstructive sleep apnea recommended for those with resistant/poorly controlled HTN, pulmonary HTN, recurrent a-fib
